Department of Radiation Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida.
Department of Radiation Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio.
Int J Radiat Oncol Biol Phys. 2018 Mar 1;100(3):606-617. doi: 10.1016/j.ijrobp.2017.11.036. Epub 2017 Dec 1.
Limited data exist to guide the treatment technique for reirradiation of recurrent or second primary squamous carcinoma of the head and neck. We performed a multi-institution retrospective cohort study to investigate the effect of the elective treatment volume, dose, and fractionation on outcomes and toxicity.
Patients with recurrent or second primary squamous carcinoma originating in a previously irradiated field (≥40 Gy) who had undergone reirradiation with intensity modulated radiation therapy (IMRT); (≥40 Gy re-IMRT) were included. The effect of elective nodal treatment, dose, and fractionation on overall survival (OS), locoregional control, and acute and late toxicity were assessed. The Kaplan-Meier and Gray's competing risks methods were used for actuarial endpoints.
From 8 institutions, 505 patients were included in the present updated analysis. The elective neck was not treated in 56.4% of patients. The median dose of re-IMRT was 60 Gy (range 39.6-79.2). Hyperfractionation was used in 20.2%. Systemic therapy was integrated for 77.4% of patients. Elective nodal radiation therapy did not appear to decrease the risk of locoregional failure (LRF) or improve the OS rate. Doses of ≥66 Gy were associated with improvements in both LRF and OS in the definitive re-IMRT setting. However, dose did not obviously affect LRF or OS in the postoperative re-IMRT setting. Hyperfractionation was not associated with improved LRF or OS. The rate of acute grade ≥3 toxicity was 22.1% overall. On multivariable logistic regression, elective neck irradiation was associated with increased acute toxicity in the postoperative setting. The rate of overall late grade ≥3 toxicity was 16.7%, with patients treated postoperatively with hyperfractionation experiencing the highest rates.
Doses of ≥66 Gy might be associated with improved outcomes in high-performance patients undergoing definitive re-IMRT. Postoperatively, doses of 50 to 66 Gy appear adequate after removal of gross disease. Hyperfractionation and elective neck irradiation were not associated with an obvious benefit and might increase toxicity.
针对复发性或第二原发头颈部鳞状细胞癌的再放疗,目前仅有少量数据可用于指导其治疗技术。我们进行了一项多机构回顾性队列研究,旨在调查选择性治疗体积、剂量和分割对结局和毒性的影响。
本研究纳入了在先前接受过放疗(≥40Gy)的区域内复发或第二原发鳞状细胞癌患者,这些患者接受了调强放疗(IMRT)再放疗(≥40Gy 再-IMRT)。评估了选择性淋巴结治疗、剂量和分割对总生存(OS)、局部区域控制以及急性和晚期毒性的影响。使用 Kaplan-Meier 和 Gray 竞争风险方法进行生存分析。
在 8 家机构中,共有 505 例患者纳入本更新分析。56.4%的患者未行选择性颈部治疗。再-IMRT 的中位剂量为 60Gy(范围 39.6-79.2Gy)。20.2%的患者采用超分割放疗。77.4%的患者接受了综合系统治疗。选择性淋巴结放疗似乎并未降低局部区域失败(LRF)的风险或提高 OS 率。在根治性再-IMRT 治疗中,剂量≥66Gy 与 LRF 和 OS 的改善相关。然而,在术后再-IMRT 治疗中,剂量并未明显影响 LRF 或 OS。超分割放疗与 LRF 或 OS 的改善无关。总体急性 3 级以上毒性发生率为 22.1%。多变量逻辑回归分析显示,术后选择性颈部照射与急性毒性增加相关。总的晚期 3 级以上毒性发生率为 16.7%,接受术后超分割放疗的患者发生率最高。
对于行根治性再-IMRT 的高绩效患者,剂量≥66Gy 可能与改善结局相关。术后,在大体疾病切除后,50 至 66Gy 的剂量似乎足够。超分割放疗和选择性颈部照射并未带来明显获益,反而可能增加毒性。